Lipidomics analysis identifies three molecular phenogroups in HFpEF, including high-risk group
An observational cohort study analyzed plasma lipidomics in 177 HFpEF patients and non-HF subjects from a Belgian cohort, with validation in an independent Canadian cohort of 177 subjects. The analysis annotated 235 unique lipids across 19 subclasses, with 96 significantly associated with HFpEF (q<0.02). Hierarchical clustering identified three distinct phenogroups with divergent lipid profiles and clinical features.
One phenogroup exhibited severe atrial dysfunction, congestion-related biomarkers, elevated cardiac and liver fibrosis indices, and markedly reduced survival. A supervised classifier using 158 shared lipids confirmed analogous lower-risk phenogroups in the Canadian cohort, though the high-risk phenotype was underrepresented. A signature of 10 lipids across six subclasses discriminated this high-risk group and correlated with disease severity markers.
Safety and tolerability data were not reported. The study has several limitations: it establishes associations only, not causation; the high-risk phenotype was underrepresented in the validation cohort; and clinical implications remain unestablished. As an observational study, these findings require validation in larger, more diverse populations before any clinical application can be considered.